Skip to main content
ViGenCell Inc. logo

ViGenCell Inc. — Investor Relations & Filings

Ticker · 308080 ISIN · KR7308080001 KO Professional, scientific and technical activities
Open in API
Filings indexed 134 across all filing types
Latest filing 2024-12-20 Major Shareholding Noti…
Country KR South Korea
Listing KO 308080

About ViGenCell Inc.

https://www.vigencell.com/en/

ViGenCell Inc. is a biotechnology company specializing in the development of immune cell therapies. The company focuses on creating treatments for cancer and other incurable diseases by enhancing a patient's own immunity. Its core technologies include the ViTier platform, which utilizes antigen-specific killer T cells to target and remove cancer cells, and the ViRanger platform, a T-cell gene therapy technology. These proprietary platforms form the basis of its pipeline of novel immune cell therapeutics designed to prolong life and improve patient outcomes.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, the relationship between the reporter and the issuer, and the purpose of the holding (management influence). This falls under the category of Major Shareholding Notification.
2024-12-20 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large-Scale Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of shares, the purpose of holding (management influence), and the relationship between the reporting entity (Gaeun Global) and special related parties (Boryung). This falls under the category of Major Shareholding Notification.
2024-12-20 Korean
최대주주변경을수반하는주식양수도계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (VigenCell) announcing a 'Change in Largest Shareholder' due to a stock purchase and sale agreement. This type of disclosure is a standard corporate event announcement regarding ownership structure changes. While it involves shares, it is not a 'Transaction in Own Shares' (buyback) nor a 'Major Shareholding Notification' (which is typically filed by the shareholder). It fits best under the 'Regulatory Filings' (RNS) category as it is a specific corporate disclosure required by the exchange.
2024-12-18 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement from a Korean company (바이젠셀) regarding the setting of a record date for the purpose of holding an Annual General Meeting (AGM). It is not the AGM presentation itself, but a formal notice of the record date for shareholder rights. Given the nature of the announcement as a regulatory disclosure regarding meeting preparation, it fits best under the RNS (Regulatory Filings) category as it is a standard corporate disclosure that does not fall into the specific categories of proxy solicitation or the meeting materials themselves.
2024-12-16 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '바이젠셀' (Vigencell) covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial information, business operations, management discussion, and financial statements, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
투자판단관련주요경영사항(임상시험계획자진취하등) (이식편대숙주질환 치료제 VMGD의 식품의약품안전처 제1/2a상 조기 종료)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory disclosure from a Korean company (Vigencell) regarding the voluntary termination of a clinical trial (VM-GD). It details the clinical trial status, the reason for termination (process optimization), and regulatory reporting dates. Since it is a specific regulatory announcement regarding clinical trial status and does not fit into financial reporting or other specific categories, it is classified as a Regulatory Filing (RNS).
2024-10-28 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.